PSA as a Useful Tool after All Forms of Treatment

Latest Updates

on Cryotherapy Online Data Registry Outcomes: Minimum Five Year Follow up Data

Authors: David Levy*, Euclid, OH, Christopher Williams, Jacksonville, FL, Thomas Polascik, Durham, NC, Stephen Jones, Cleveland, OH Abstract: MP45-16 in 2014 AUA Convention in Orlando, Florida

Introduction and Objectives

We report a comprehensive update of 5 year COLD Registry outcomes for patients undergoing primary whole gland prostate cryoablation.

Methods

A risk stratified cohort of 1,111 treatment naïve patients who underwent primary whole gland cryoablation was identified. 5 year biochemical progression free Kaplan Meier survival curves were constructed based on Phoenix definition.

Results

• Overall bPFS* was: 79.9%, 64.1% and 68.1%, low, intermediate and high risk, respectively, (Figure 1).

• For 817 (73.5%) patients with nadir PSA < 0.4 ng/ml, bPFS* was 91%, 80.5%, and 77.6%, low, intermediate and high risk, respectively.

• Patients with a nadir PSA > 0.4 ng/ml demonstrated 24-month biochemical progression rates in excess of 34%.

• Continence was preserved in 93.4% of patients, while 5.9% of patients had retention and 0.5% developed a rectal fistula.

• Potency data entered into the Registry data base revealed that 35% of patients were potent at 12 months.

Conclusions

• 5 year bPFS* following prostate cryoablation is comparable to surgical and radiation outcomes across all risk categories with a lower likelihood of procedure related complications.

• A nadir PSA > 0.4 ng/ml predicts a high likelihood of biochemical progression and warrants close follow up.

* bPFS: biochemical progression free survival Date & Time: May 18, 2014 3:30 PM-5:30 PM

Session Title: Prostate Cancer: Localized III Sources of Funding: none

Abstracts printed from AUA2014.org

Note

Thank you for reading the post. Before you go, please leave your comment/suggest for improvement as well as helping others; I do appreciate it.